NCT05401162Recruiting
Chemotherapy Supported by Autologous Hematopoietic Stem Cells
Conventional Dose Chemotherapy for Ovarian Cancer Supported by Autologous Haematopoietic Stem Cell Transfusion
Source: ClinicalTrials.gov · Last updated 29 Jun 2026
Brief summary (registry, in English)
The aim of this project is to use autologous haematopoietic stem cell transfusion support to promote the reconstruction of haematopoietic function after chemotherapy for ovarian cancer. To explore the impact of stored haematopoietic stem cell support therapy on bone marrow protection after conventional chemotherapy for ovarian cancer in order to facilitate its clinical application.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 29 May 2022
- Start date
- Apr 2022
- Primary completion date
- May 2027
- Lead sponsor
- Chongqing University Cancer Hospital
- Diseases
- Ovarian cancer
- NCT number
- NCT05401162
What you commit to
- Study type: Interventional
- Planned participants: 40
- From Apr 2022 to the primary completion date, May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- previous history of allogeneic stem cell transplantation or organ transplantation;
- patients with chemotherapy contraindications;
Other illness
- patients with bone marrow disease;
- patient has severe cardiac insufficiency;
- patients with active bleeding and autoimmune thrombocytopenic purpura;
- positive for human immunodeficiency virus (HIV);
- acute or chronic active hepatitis B or hepatitis C infection.
Other
- central nervous system or soft meningeal or bone or bone marrow metastases confirmed by imaging or pathology;
Who the study is looking for
- 18-60 years old;
- there are chemotherapy indicators for ovarian cancer;
- ovarian cancer diagnosed by histopathology;
- recurrent and metastatic ovarian cancer;
- the Eastern Cooperative Oncology Group (ECOG) performance status score≤1;
- the expected survival time was more than 3 months;
- pre-menopausal women (post-menopausal women must have been postmenopausal for at least 12 months to be considered infertile), and the serum pregnancy test results are negative;
- all patients must agree to take effective contraceptive measures during the study period and within 6 months after stopping treatment;
- the subjects voluntarily participate in this clinical trial sign an informed consent form and are able to complete the study procedures and follow-up examinations;
- bone marrow function is good,ability to perform stem cell mobilisation and collection.
Age in the registry: 18 years to 60 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Chongqing University Cancer Hospital Coordinator of this site? Confirm its status | Chongqing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.